How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy
Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…
CertaraJanuary 22, 2026
Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus
Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…
CertaraJanuary 16, 2026
Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies
Watch this on-demand webinar featuring former regulators as they share global regulatory trends and clinical…
CertaraJanuary 14, 2026
Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…
CertaraJanuary 7, 2026
A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection
This study synthesizes data from a large body of clinical trials to evaluate rates of…
CertaraDecember 18, 2025
